Q9R0T8
PR
Gene name |
Ikbke (Ikke, Ikki) |
Protein name |
Inhibitor of nuclear factor kappa-B kinase subunit epsilon |
Names |
Epithelial cadherin, E-cadherin, Uvomorulin, I-kappa-B kinase epsilon, IKK-E, IKK-epsilon, IkBKE, Inducible I kappa-B kinase, IKK-i |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:56489 |
EC number |
2.7.11.10: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9R0T8
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9R0T8-F1 | Predicted | AlphaFoldDB |
34 variants for Q9R0T8
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388496441 | 88 | Y>H | No | EVA | |
| rs3388497882 | 119 | V>E | No | EVA | |
| rs3388496477 | 125 | H>L | No | EVA | |
| rs3388496610 | 195 | Q>R | No | EVA | |
| rs3388494568 | 235 | Y>* | No | EVA | |
| rs3388494782 | 236 | R>K | No | EVA | |
| rs3388497009 | 244 | G>W | No | EVA | |
| rs3388495291 | 272 | G>E | No | EVA | |
| rs3410236044 | 280 | I>L | No | EVA | |
| rs252594321 | 300 | A>S | No | EVA | |
| rs3388496942 | 325 | Y>H | No | EVA | |
| rs33465472 | 328 | A>T | No | EVA | |
| rs3390640864 | 329 | H>P | No | EVA | |
| rs3388498570 | 342 | Q>H | No | EVA | |
| rs3388498318 | 344 | N>D | No | EVA | |
| rs3388495347 | 355 | E>D | No | EVA | |
| rs3388498365 | 356 | G>D | No | EVA | |
| rs236247070 | 376 | S>G | No | EVA | |
| rs3388500317 | 393 | A>T | No | EVA | |
| rs3388494545 | 398 | A>T | No | EVA | |
| rs33467259 | 471 | S>G | No | EVA | |
| rs3388497942 | 481 | S>N | No | EVA | |
| rs31050360 | 483 | A>S | No | EVA | |
| rs3388494530 | 529 | L>P | No | EVA | |
| rs33464105 | 541 | K>R | No | EVA | |
| rs3388498232 | 603 | Y>F | No | EVA | |
| rs3388495339 | 621 | Q>E | No | EVA | |
| rs3390640836 | 627 | I>S | No | EVA | |
| rs3390604781 | 630 | S>C | No | EVA | |
| rs3390650667 | 630 | S>T | No | EVA | |
| rs3388494695 | 650 | D>A | No | EVA | |
| rs230811997 | 672 | H>R | No | EVA | |
| rs3388494725 | 705 | I>T | No | EVA | |
| rs3388496931 | 717 | V>A | No | EVA |
No associated diseases with Q9R0T8
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.10 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
4 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| mitochondrial membrane | Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| PML body | A class of nuclear body; they react against SP100 auto-antibodies (PML, promyelocytic leukemia); cells typically contain 10-30 PML bodies per nucleus; alterations in the localization of PML bodies occurs after viral infection. |
8 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| identical protein binding | Binding to an identical protein or proteins. |
| IkappaB kinase activity | Catalysis of the reaction: ATP + IkappaB protein = ADP + IkappaB phosphoprotein. |
| K48-linked polyubiquitin modification-dependent protein binding | Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 48 in the target protein. |
| NF-kappaB-inducing kinase activity | Catalysis of the phosphorylation of the alpha or beta subunit of the inhibitor of kappaB kinase complex (IKK). |
| protein kinase activity | Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP. |
| protein serine/threonine kinase activity | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate. |
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
15 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to virus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
| gene expression | The process in which a gene's sequence is converted into a mature gene product (protein or RNA). This includes the production of an RNA transcript and its processing, translation and maturation for protein-coding genes. |
| immune response | Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. |
| interleukin-17-mediated signaling pathway | The series of molecular signals initiated by interleukin-17 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| intrinsic apoptotic signaling pathway in response to DNA damage | The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the detection of DNA damage, and ends when the execution phase of apoptosis is triggered. |
| mRNA stabilization | Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules. |
| peptidyl-serine phosphorylation | The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine. |
| positive regulation of DNA-binding transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription. |
| positive regulation of I-kappaB kinase/NF-kappaB signaling | Any process that activates or increases the frequency, rate or extent of I-kappaB kinase/NF-kappaB signaling. |
| positive regulation of lipid storage | Any process that increases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. |
| positive regulation of type I interferon-mediated signaling pathway | Any process that increases the rate, frequency or extent of a type I interferon-mediated signaling pathway. |
| protein phosphorylation | The process of introducing a phosphate group on to a protein. |
| regulation of protein-containing complex assembly | Any process that modulates the frequency, rate or extent of protein complex assembly. |
| response to interferon-beta | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus. Interferon-beta is a type I interferon. |
| response to type I interferon | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type I interferon stimulus. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. |
3 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9VEZ5 | IKKbeta | Inhibitor of nuclear factor kappa-B kinase subunit beta | Drosophila melanogaster (Fruit fly) | PR |
| O14920 | IKBKB | Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (Human) | PR |
| Q14164 | IKBKE | Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MQSTTNYLWH | TDDLLGQGAT | ASVYKARNKK | SGEVVAVKVF | NSASYRRPPE | VQVREFEVLR |
| 70 | 80 | 90 | 100 | 110 | 120 |
| RLNHQNIVKL | FAVEETGGSR | QKVLIMEYCS | SGSLLSVLED | PENTFGLSEE | EFLVVLRCVV |
| 130 | 140 | 150 | 160 | 170 | 180 |
| AGMNHLRENG | IVHRDIKPGN | IMRLVGEEGQ | SIYKLSDFGA | ARKLDDDEKF | VSVYGTEEYL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| HPDMYERAVL | RKPQQKAFGV | TVDLWSIGVT | LYHAATGSLP | FIPFGGPRRN | KEIMYRITTE |
| 250 | 260 | 270 | 280 | 290 | 300 |
| KPAGAISGTQ | KQENGPLEWS | YSLPITCRLS | MGLQNQLVPI | LANILEVEED | KCWGFDQFFA |
| 310 | 320 | 330 | 340 | 350 | 360 |
| ETSDILQRTV | IHVFSLPQAV | LHHVYIHAHN | TIAIFLEAVY | EQTNVTPKHQ | EYLFEGHPCV |
| 370 | 380 | 390 | 400 | 410 | 420 |
| LEPSLSAQHI | AHTAASSPLT | LFSMSSDTPK | GLAFRDPALD | VPKFVPKVDL | QADYSTAKGV |
| 430 | 440 | 450 | 460 | 470 | 480 |
| LGAGYQALWL | ARVLLDGQAL | MLRGLHWVLE | VLQDTCQQTL | EVTRTALLYL | SSSLGTERFS |
| 490 | 500 | 510 | 520 | 530 | 540 |
| SGAGMPDVQE | RKEATELRTR | LQTLSEILSK | CSHNVTETQR | SLSCLGEELL | KNRDQIHEDN |
| 550 | 560 | 570 | 580 | 590 | 600 |
| KSIQKIQCCL | DKMHFIYKQF | KKSRMRPGLS | YNEEQIHKLD | KVNFSHLAKR | LLQVFQEECV |
| 610 | 620 | 630 | 640 | 650 | 660 |
| QTYQVSLVTH | GKRMRQVQRA | QNHLHLIGHS | VATCNSEARG | AQESLNKIFD | QLLLDRASEQ |
| 670 | 680 | 690 | 700 | 710 | |
| GAEVSPQPMA | PHPGPDPKDL | VFHMQELCND | MKLLAFDLQD | NNRLIERLHR | VPSAPDV |